Patents, ethics, biosafety and regulation using CRISPR technology

Zandile Nxumalo; Mutsa M Takundwa; Deepak B Thimiri Govinda Raj

doi:10.1016/bs.pmbts.2021.01.023

Patents, ethics, biosafety and regulation using CRISPR technology

Prog Mol Biol Transl Sci. 2021:181:345-365. doi: 10.1016/bs.pmbts.2021.01.023. Epub 2021 Feb 24.

Authors

Zandile Nxumalo¹, Mutsa M Takundwa², Deepak B Thimiri Govinda Raj³

Affiliations

¹ Synthetic Nanobiotechnology and Biomachines Group, Centre for Synthetic Biology and Precision Medicine, CSIR, Pretoria, South Africa.
² Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.
³ Synthetic Nanobiotechnology and Biomachines Group, Centre for Synthetic Biology and Precision Medicine, CSIR, Pretoria, South Africa. Electronic address: dgovindaraj@csir.co.za.

PMID: 34127200
DOI: 10.1016/bs.pmbts.2021.01.023

Abstract

In this review chapter, we provide full comprehensive analysis on the patent, ethics and biosafety regulation with respect to the application of CRISPR technology in mammalian systems. We focused on recent development in CRISPR technology and its patent landscape between countries such as US, European Union, China and Australia. Further, we emphasized on the current scenarios on the ethics regulations with respect to CRISPR research, its applicability in patent and technology transfer. Finally, we elaborated on the biosafety regulation on CRISPR/Cas9 technology application in both mammalian and non-mammalian host system.

Keywords: CRISPR; Ethics and biosafety regulation; Patent.

Publication types

Review

MeSH terms

Animals
CRISPR-Cas Systems* / genetics
China
Containment of Biohazards*
Humans
Technology